| # | Pathway | Proteins |
|---|
| 1 | Ribosome | ENSAPLP00000004886, ENSAPLP00000004776, ENSAPLP00000012634, ENSAPLP00000014148, ENSAPLP00000007620, ENSAPLP00000007673, ENSAPLP00000011518, ENSAPLP00000015662, ENSAPLP00000009200, ENSAPLP00000015617, ENSAPLP00000016333, ENSAPLP00000014372, ENSAPLP00000001900, ENSAPLP00000008154 |
| 2 | ECM-receptor interaction | ENSAPLP00000013159, ENSAPLP00000014466, ENSAPLP00000009107, ENSAPLP00000013787, ENSAPLP00000011738, ENSAPLP00000000534, ENSAPLP00000000439, ENSAPLP00000016096 |
| 3 | Hypertrophic cardiomyopathy (HCM) | ENSAPLP00000013159, ENSAPLP00000015089, ENSAPLP00000009107, ENSAPLP00000004152, ENSAPLP00000011738, ENSAPLP00000012136, ENSAPLP00000003219 |
| 4 | Dilated cardiomyopathy | ENSAPLP00000013159, ENSAPLP00000015089, ENSAPLP00000009107, ENSAPLP00000004152, ENSAPLP00000011738, ENSAPLP00000012136, ENSAPLP00000003219 |
| 5 | beta-Alanine metabolism | ENSAPLP00000008767, ENSAPLP00000003758, ENSAPLP00000008299, ENSAPLP00000004066 |
| 6 | Malaria | ENSAPLP00000007488, ENSAPLP00000005443, ENSAPLP00000011743 |
| 7 | Protein processing in endoplasmic reticulum | ENSAPLP00000010398, ENSAPLP00000000447, ENSAPLP00000002711, ENSAPLP00000005679, ENSAPLP00000014094, ENSAPLP00000011000, ENSAPLP00000010630, ENSAPLP00000014548 |
| 8 | Focal adhesion | ENSAPLP00000013159, ENSAPLP00000014466, ENSAPLP00000010282, ENSAPLP00000009107, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000011738, ENSAPLP00000009699, ENSAPLP00000000439, ENSAPLP00000016096 |
| 9 | PI3K-Akt signaling pathway | ENSAPLP00000013159, ENSAPLP00000014466, ENSAPLP00000009107, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000011738, ENSAPLP00000000439, ENSAPLP00000014548, ENSAPLP00000016096 |
| 10 | Cardiac muscle contraction | ENSAPLP00000015089, ENSAPLP00000012136, ENSAPLP00000003219, ENSAPLP00000014736 |
| 11 | Tyrosine metabolism | ENSAPLP00000003758, ENSAPLP00000012915, ENSAPLP00000004066 |
| 12 | Phenylalanine metabolism | ENSAPLP00000003758, ENSAPLP00000004066 |
| 13 | Regulation of actin cytoskeleton | ENSAPLP00000013159, ENSAPLP00000009727, ENSAPLP00000010282, ENSAPLP00000009107, ENSAPLP00000006504, ENSAPLP00000003050, ENSAPLP00000009699, ENSAPLP00000005955 |
| 14 | Shigellosis | ENSAPLP00000009727, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000009699 |
| 15 | Histidine metabolism | ENSAPLP00000008767, ENSAPLP00000008299 |
| 16 | Vitamin digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561 |
| 17 | Thyroid hormone synthesis | ENSAPLP00000010398, ENSAPLP00000002711, ENSAPLP00000014548 |
| 18 | Fat digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561 |
| 19 | cAMP signaling pathway | ENSAPLP00000016230, ENSAPLP00000006504, ENSAPLP00000003050, ENSAPLP00000015529 |
| 20 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ENSAPLP00000013159, ENSAPLP00000009107, ENSAPLP00000004152, ENSAPLP00000011738 |
| 21 | Adherens junction | ENSAPLP00000003052, ENSAPLP00000003050, ENSAPLP00000015529, ENSAPLP00000009699 |
| 22 | Viral myocarditis | ENSAPLP00000004152, ENSAPLP00000003050, ENSAPLP00000011738 |
| 23 | African trypanosomiasis | ENSAPLP00000007488, ENSAPLP00000005443 |
| 24 | Axon guidance | ENSAPLP00000009975, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000007333 |
| 25 | Tight junction | ENSAPLP00000010282, ENSAPLP00000007261, ENSAPLP00000006504, ENSAPLP00000007172, ENSAPLP00000005955 |
| 26 | TGF-beta signaling pathway | ENSAPLP00000015529, ENSAPLP00000013831 |
| 27 | Parkinson's disease | ENSAPLP00000009300, ENSAPLP00000012915, ENSAPLP00000010540, ENSAPLP00000014736, ENSAPLP00000014609 |
| 28 | Salmonella infection | ENSAPLP00000009727, ENSAPLP00000003050, ENSAPLP00000005955 |
| 29 | Glycine, serine and threonine metabolism | ENSAPLP00000003758, ENSAPLP00000004066 |
| 30 | Proteoglycans in cancer | ENSAPLP00000009107, ENSAPLP00000006504, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000013831, ENSAPLP00000013792 |
| 31 | Bacterial invasion of epithelial cells | ENSAPLP00000005099, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000009699 |
| 32 | Estrogen signaling pathway | ENSAPLP00000000447, ENSAPLP00000011996, ENSAPLP00000014548 |
| 33 | Legionellosis | ENSAPLP00000000447, ENSAPLP00000004358 |
| 34 | Leukocyte transendothelial migration | ENSAPLP00000010282, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000009699 |
| 35 | Amyotrophic lateral sclerosis (ALS) | ENSAPLP00000003050, ENSAPLP00000012498 |
| 36 | Type I diabetes mellitus | ENSAPLP00000004358 |
| 37 | Toxoplasmosis | ENSAPLP00000000447, ENSAPLP00000009107, ENSAPLP00000011738 |
| 38 | Platelet activation | ENSAPLP00000010282, ENSAPLP00000009107, ENSAPLP00000004030, ENSAPLP00000003867 |
| 39 | Influenza A | ENSAPLP00000003661, ENSAPLP00000000447, ENSAPLP00000015529 |
| 40 | Ascorbate and aldarate metabolism | ENSAPLP00000008299 |
| 41 | Renal cell carcinoma | ENSAPLP00000003050, ENSAPLP00000015529 |
| 42 | Ribosome biogenesis in eukaryotes | ENSAPLP00000013416, ENSAPLP00000006775 |
| 43 | Prostate cancer | ENSAPLP00000015529, ENSAPLP00000014548 |
| 44 | Arginine and proline metabolism | ENSAPLP00000008767, ENSAPLP00000008299 |
| 45 | Protein export | ENSAPLP00000002711 |
| 46 | Measles | ENSAPLP00000000447, ENSAPLP00000002414 |
| 47 | Antigen processing and presentation | ENSAPLP00000000447, ENSAPLP00000002711 |
| 48 | Adrenergic signaling in cardiomyocytes | ENSAPLP00000015089, ENSAPLP00000012136, ENSAPLP00000003219 |
| 49 | Alzheimer's disease | ENSAPLP00000009300, ENSAPLP00000011743, ENSAPLP00000014736, ENSAPLP00000014609 |
| 50 | Protein digestion and absorption | ENSAPLP00000000439, ENSAPLP00000016096 |
| 51 | Neuroactive ligand-receptor interaction | ENSAPLP00000016230 |
| 52 | Huntington's disease | ENSAPLP00000009300, ENSAPLP00000005099, ENSAPLP00000015529, ENSAPLP00000014736, ENSAPLP00000014609 |
| 53 | Prion diseases | ENSAPLP00000000447, ENSAPLP00000002711 |
| 54 | Cocaine addiction | ENSAPLP00000012915 |
| 55 | Thyroid cancer | ENSAPLP00000015089 |
| 56 | Glycerolipid metabolism | ENSAPLP00000008299 |
| 57 | Ras signaling pathway | ENSAPLP00000003083, ENSAPLP00000006504, ENSAPLP00000003050 |
| 58 | Non-alcoholic fatty liver disease (NAFLD) | ENSAPLP00000003050, ENSAPLP00000014736, ENSAPLP00000014609 |
| 59 | Hippo signaling pathway - fly | ENSAPLP00000003083, ENSAPLP00000012596 |
| 60 | RNA degradation | ENSAPLP00000014331, ENSAPLP00000004358 |
| 61 | Amoebiasis | ENSAPLP00000012216, ENSAPLP00000011738, ENSAPLP00000009699 |
| 62 | Small cell lung cancer | ENSAPLP00000009107, ENSAPLP00000011738 |
| 63 | Notch signaling pathway | ENSAPLP00000015529 |
| 64 | MicroRNAs in cancer | ENSAPLP00000014466, ENSAPLP00000003219, ENSAPLP00000015529 |
| 65 | Glucagon signaling pathway | ENSAPLP00000015529, ENSAPLP00000010189 |
| 66 | Porphyrin and chlorophyll metabolism | ENSAPLP00000002793 |
| 67 | NOD-like receptor signaling pathway | ENSAPLP00000014548 |
| 68 | Pentose and glucuronate interconversions | ENSAPLP00000008299 |
| 69 | HTLV-I infection | ENSAPLP00000013416, ENSAPLP00000006504, ENSAPLP00000015529 |
| 70 | Mineral absorption | ENSAPLP00000015679 |
| 71 | Pathways in cancer | ENSAPLP00000015089, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000011738, ENSAPLP00000015529, ENSAPLP00000014548 |
| 72 | Spliceosome | ENSAPLP00000012296, ENSAPLP00000003661, ENSAPLP00000000447, ENSAPLP00000014331 |
| 73 | Wnt signaling pathway | ENSAPLP00000003050, ENSAPLP00000015529 |
| 74 | Hematopoietic cell lineage | ENSAPLP00000013159 |
| 75 | Oxidative phosphorylation | ENSAPLP00000009300, ENSAPLP00000014736, ENSAPLP00000014609 |
| 76 | Complement and coagulation cascades | ENSAPLP00000004030, ENSAPLP00000003867 |
| 77 | Amphetamine addiction | ENSAPLP00000012915 |
| 78 | MAPK signaling pathway | ENSAPLP00000000447, ENSAPLP00000006504, ENSAPLP00000003050 |
| 79 | Vascular smooth muscle contraction | ENSAPLP00000005955, ENSAPLP00000002381 |
| 80 | Rap1 signaling pathway | ENSAPLP00000009727, ENSAPLP00000009107, ENSAPLP00000003050 |
| 81 | HIF-1 signaling pathway | ENSAPLP00000015679, ENSAPLP00000015529 |
| 82 | Leishmaniasis | ENSAPLP00000009107 |
| 83 | Colorectal cancer | ENSAPLP00000003050 |
| 84 | Tryptophan metabolism | ENSAPLP00000008299 |
| 85 | Prolactin signaling pathway | ENSAPLP00000012915 |
| 86 | Pancreatic cancer | ENSAPLP00000003050 |
| 87 | Starch and sucrose metabolism | ENSAPLP00000010189 |
| 88 | VEGF signaling pathway | ENSAPLP00000003050 |
| 89 | Tuberculosis | ENSAPLP00000004358, ENSAPLP00000015529 |
| 90 | Toll-like receptor signaling pathway | ENSAPLP00000003050 |
| 91 | Lysine degradation | ENSAPLP00000008299 |
| 92 | Jak-STAT signaling pathway | ENSAPLP00000015529 |
| 93 | Vasopressin-regulated water reabsorption | ENSAPLP00000010780 |
| 94 | Viral carcinogenesis | ENSAPLP00000003083, ENSAPLP00000003050, ENSAPLP00000015529 |
| 95 | Pertussis | ENSAPLP00000009107 |
| 96 | Endocrine and other factor-regulated calcium reabsorption | ENSAPLP00000005099 |
| 97 | B cell receptor signaling pathway | ENSAPLP00000003050 |
| 98 | Long-term potentiation | ENSAPLP00000015529 |
| 99 | Pancreatic secretion | ENSAPLP00000003050 |
| 100 | Insulin signaling pathway | ENSAPLP00000003052, ENSAPLP00000010189 |
| 101 | Herpes simplex infection | ENSAPLP00000012296, ENSAPLP00000015529 |
| 102 | Choline metabolism in cancer | ENSAPLP00000003050 |
| 103 | Epstein-Barr virus infection | ENSAPLP00000013416, ENSAPLP00000000447, ENSAPLP00000015529 |
| 104 | Natural killer cell mediated cytotoxicity | ENSAPLP00000003050 |
| 105 | Fc epsilon RI signaling pathway | ENSAPLP00000003050 |
| 106 | Vibrio cholerae infection | ENSAPLP00000010398 |
| 107 | Aminoacyl-tRNA biosynthesis | ENSAPLP00000002793 |
| 108 | Melanogenesis | ENSAPLP00000015529 |
| 109 | Synaptic vesicle cycle | ENSAPLP00000005099 |
| 110 | Pyrimidine metabolism | ENSAPLP00000002225 |
| 111 | PPAR signaling pathway | ENSAPLP00000003052 |
| 112 | Citrate cycle (TCA cycle) | ENSAPLP00000016003 |
| 113 | Insulin resistance | ENSAPLP00000010189 |
| 114 | FoxO signaling pathway | ENSAPLP00000015529 |
| 115 | Epithelial cell signaling in Helicobacter pylori infection | ENSAPLP00000003050 |
| 116 | Osteoclast differentiation | ENSAPLP00000003050 |
| 117 | Pyruvate metabolism | ENSAPLP00000008299 |
| 118 | Serotonergic synapse | ENSAPLP00000016230 |
| 119 | Fatty acid degradation | ENSAPLP00000008299 |
| 120 | Cell adhesion molecules (CAMs) | ENSAPLP00000009107 |
| 121 | Cell cycle | ENSAPLP00000015529 |
| 122 | Sphingolipid signaling pathway | ENSAPLP00000003050 |
| 123 | AMPK signaling pathway | ENSAPLP00000010780 |
| 124 | Phospholipase D signaling pathway | ENSAPLP00000006504 |
| 125 | Thyroid hormone signaling pathway | ENSAPLP00000015529 |
| 126 | Phagosome | ENSAPLP00000009107, ENSAPLP00000003050 |
| 127 | Endocytosis | ENSAPLP00000000447, ENSAPLP00000005099, ENSAPLP00000010780, ENSAPLP00000003542 |
| 128 | Glycolysis / Gluconeogenesis | ENSAPLP00000008299 |
| 129 | Valine, leucine and isoleucine degradation | ENSAPLP00000008299 |
| 130 | Fc gamma R-mediated phagocytosis | ENSAPLP00000003050 |
| 131 | Hepatitis B | ENSAPLP00000015529 |
| 132 | Hippo signaling pathway | ENSAPLP00000003083 |
| 133 | Neurotrophin signaling pathway | ENSAPLP00000003050 |
| 134 | Pathogenic Escherichia coli infection | ENSAPLP00000009107 |
| 135 | Dopaminergic synapse | ENSAPLP00000012915 |
| 136 | Calcium signaling pathway | ENSAPLP00000016230 |
| 137 | Alcoholism | ENSAPLP00000012915 |
| 138 | Purine metabolism | ENSAPLP00000002225 |
| 139 | Chemokine signaling pathway | ENSAPLP00000003050 |
| 140 | Metabolic pathways (no map in kegg database) | ENSAPLP00000008767, ENSAPLP00000009300, ENSAPLP00000003758, ENSAPLP00000008299, ENSAPLP00000016003, ENSAPLP00000002225, ENSAPLP00000002793, ENSAPLP00000010189, ENSAPLP00000016332, ENSAPLP00000012915, ENSAPLP00000014736, ENSAPLP00000014609, ENSAPLP00000004066 |
| 141 | Lysosome | ENSAPLP00000005099 |
| 142 | RNA transport | ENSAPLP00000013416 |